Apolipoprotein Inhibitor

Olezarsen sodium scrambled negative control is the sequence scrambled negative control of Olezarsen sodium.

Cy3 labled Zerlasiran sodium is a Cy3 labled Zerlasiran sodium (HY-147425A). Zerlasiran sodium is a siRNA targeting apolipoprotein A (ApoA). Zerlasiran sodium targets hepatic ApoA synthesis via RNA interference to degrade encoding mRNA. Zerlasiran sodium can be used for the research of atherosclerotic cardiovascular disease and elevated ApoA levels.

apoB (4372-4392) is a potent lipoprotein(a) assembly inhibitor, with an IC₅₀ of 40 μM. apoB (4372-4392) can noncovalently bind to apolipoprotein(a) with high affinity.

Lp(a)-IN-5 (Compound A) is an orally active lipoprotein (a) (Lp(a)) inhibitor. Lp(a)-IN-5 inhibits the assembly of Apo(a) and ApoB proteins with an IC₅₀ value of 0.41 nM. Lp(a)-IN-5 is promising for research of diseases related to elevated plasma Lp(a) levels, such as cardiovascular diseases.

Tisbesiran is an apolipoprotein(a) (apo(a)) synthesis inhibitor. Tisbesiran is a trivalent GalNAc-conjugated double-stranded siRNA with a mixed modification of 2′-OMe/2′-F/P-thio. Its antisense strand targets the KIV-2 repeat region of human apo(a) (LPA) mRNA, thereby inhibiting apolipoprotein(a) synthesis and reducing plasma Lp(a). Tisbesiran can be used for research on Lp(a)-mediated atherosclerotic cardiovascular disease.